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Chromosomal rearrangements of band 19q13.4 are frequent cytogenetic alterations in benign thyroid adenomas.
Apparently, these alterations lead to the upregulation of genes encoding microRNAs of two clusters mapping
to the breakpoint region, i.e. miR-371-3 and C19MC. Since members of both clusters have been associated with
neoplastic growth in other tumor entities the question arises whether or not their upregulation predisposes to
malignant transformation of follicular cells of the thyroid. To address this question we have quantified the
expression of miR-372 and miR-520c-3p in samples of 114 thyroid cancers including eight anaplastic thyroid
carcinomas, 25 follicular thyroid carcinomas, 78 papillary thyroid carcinomas (including 13 follicular variants
thereof), two medullary thyroid carcinomas and one oncocytic thyroid carcinoma. Additionally, we quantified
miR-371a-3p and miR-519a-3p in selected samples. While in neither of the cases miR-520c-3p and miR-519a-3p
were found to be upregulated, one papillary and one anaplastic thyroid carcinoma, respectively, showed
upregulation of miR-372 and miR-371a-3p. However, in these cases fluorescence in situ hybridization did not
reveal rearrangements of the common breakpoint region as affected in adenomas. Thus, these rearrangements
do apparently not play a major role as first steps in malignant transformation of the thyroid epithelium.
Moreover, there is no evidence that 19q13.4 rearrangements characterize a subgroup of thyroid adenomas
associated with a higher risk to undergo malignant transformation. Vice versa, the mechanisms by which
19q13.4 rearrangements contribute to benign tumorigenesis in the thyroid remain to be elucidated.
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MicroRNAs (miRNAs) are short non protein-coding
RNA molecules that negatively regulate gene
expression by binding to the 3' UTR of mRNA thereby
inhibiting its transcription or promoting nucleolytic
cleavage. Abnormal expression patterns of miRNAs
have been found in many types of tumors and, as to
malignant tumors, are able to promote cancer specific
properties like metastasis, angiogenesis or proliferation
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reproduction in any medium, provided the orWe have been able to show that the most frequent
recurrent chromosomal rearrangement in benign thy-
roid tumors, i.e. translocations of chromosomal band
19q13, initially described more than 20 years ago [3],
clusters within a 150 kb region assigned to 19q13.4
[4]. More recently, we have demonstrated that these
aberrations target the two miRNA gene clusters
C19MC (chromosome 19 microRNA cluster) and miR-
371-3 resulting in their transcriptional activation likely
due to juxtaposing them to transcriptional activators
[5] or by removal of CpG rich regions [6] upstream of
the clusters.
Normally, the expression of miRNAs of both clusters
is abundant in embryonic stem cells (ESC) [7-12] and
later becomes repressed in the embryo whereas expres-
sion of both clusters persists in the placenta until birthtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the paternal allele only because the maternal allele is
silenced by methylation [15]. However, the biological
function of these miRNAs for the placenta develop-
ment is not yet understood. In a recent set of interest-
ing papers on miRNAs from the miR-371-3 cluster in
tumors, their overexpression has been correlated with
an invasive cellular behavior [16-19]. On the other
hand, miRNAs of C19MC have been described to have
oncogenic as well as tumorsuppressive characteristics
[for summary see [20]].
Nevertheless, it has not yet been tested if, akin to
adenomas with 19q13.4 rearrangements, subsets of
thyroid carcinomas also overexpress the genes of both
clusters which may indicate that those malignant tumors
are derived from pre-existing benign lesions. We there-
fore examined 114 formalin-fixed, paraffin-embedded
(FFPE) tumor samples of the major histological groups
of thyroid cancer for their expression of miR-372 and
miR-520c-3p, respectively. Selected samples were also
analyzed for their expression of miR-371a-3p and miR-
519a-3p. We found no cases expressing both miRNAs
within the range observed in adenomas with 19q13.4 rear-
rangements. Interestingly though, two tumors expressed
miR-372 and miR-371a-3p at a comparable level.
Results
By quantitative real-time PCR we first measured miR-
372 levels in 114 thyroid carcinomas of different histo-
logical groups. Our samples included eight anaplastic
thyroid carcinomas (ATC), 25 follicular thyroid car-
cinomas (FTC), 78 papillary thyroid carcinomas (PTC),
including 13 follicular variants of PTC, two medullary
thyroid carcinomas (MTC) and one oncocytic thyroid
carcinoma (OTC). As a subgroup of thyroid adenomas is
shown to overexpress both clusters due to chromosomal
rearrangements involving chromosomal band 19q13.4
[5] we used a thyroid adenoma sample (S1016) of
this subgroup as a positive control for quantification of
miR-372, respectively.
Compared to normal thyroid tissue miR-372 was
clearly upregulated in only two tumors (KS 13 and KS
100) (2.4%) (Figure 1A). KS 13 is a follicular variant of a
PTC and KS 100 is an ATC (Figure 1B, C).
In order to validate that overexpression of miR-372 is
indeed tumor-specific we used another FFPE block of
case KS 13 to separate the surrounding tissue from the
tumor. Overexpression of miR-372 was clearly confined
to the tumor and absent in the surrounding normal
thyroid tissue (Figure 2).
To further corroborate our results we next quantified
another member of miR-371-3 (i.e. miR-371a-3p) in KS
13 and KS 100 and in one sample of each major histo-
logical subgroup (ATC, PTC, FTC), respectively. Akin towhat was observed for miR-372, miR-371a-3p was upre-
gulated in KS 13 and KS 100 with expression levels sim-
ilar to or clearly exceeding that of the positive control
S1016 whereas miR-371a-3p was not upregulated in the
three other samples (Figure 3A).
We then focused on the cluster C19MC and quantified
the expression of miR-520c-3p in all of the 114 thyroid
carcinoma samples and miR-519a-3p in the same sam-
ples that were used to quantify miR-371a-3p. Neither
miR-520c-3p nor miR-519a-3p were upregulated in
any of the samples but expressed at a level comparable
to that of the normal thyroid tissue; at most, a slight
increase could be noted for miR-519a-3p in KS 13 and
KS 100 which, however, did not reach levels comparable
to that of the thyroid adenoma with 19q13.4 rearrange-
ment (Figure 3B,C).
In order to check whether the two samples KS 100
and KS 13 showing an increased expression of miR-372
and miR-371a-3p harbor 19q13.4 rearrangements we
performed fluorescence in situ hybridization (FISH)
with a dual-color break-apart rearrangement probe cov-
ering the thyroid adenoma breakpoint cluster 19q13.4
(TBPC19) [4]. In none of the nuclei of either of the two
cases or of the negative control signal patterns corre-
sponding to 19q13.4 rearrangements were detected
(Figure 4A,B). As a positive control cytologic smears of
adenoma S1016 were used. In this case, FISH revealed
83.5% positive nuclei (one pair of colocalized signals,
two separate signals) (Figure 4C). G-banding analysis
of this case revealed an apparently balanced transloca-
tion t(2;19)(p13;q13.4) (Figure 4D).
Discussion
Whereas adenomas and goiters belong to highly preva-
lent lesions of the thyroid not only in iodine-deficient
regions malignant thyroid tumors are rare. Both papil-
lary and follicular carcinomas of the thyroid are sup-
posed to originate from the thyroid epithelium. At least
for the follicular carcinomas a possible continuum from
thyroid adenomas to follicular carcinomas has been pro-
posed [21]. This idea is at least supported by a particular
subtype of follicular tumors i.e. those characterized by a
PAX8-PPARγ fusion due to a chromosomal rearrange-
ment between chromosomal bands 2q13 and 3p25. As
witnessed by the results of several studies, this abnor-
mality can be found in follicular adenomas as well as
in carcinomas [22-24]. However, the question arises whe-
ther or not other genetic subtypes of thyroid adenomas
may predispose to malignant transformation. Recently, we
have been able to demonstrate that translocations of
chromosomal band 19q13.4, a frequent genetic alteration
in thyroid adenomas, activate two miRNA clusters on
the long arm of chromosome 19 [5]. Of these, C19MC is
the largest human miRNA cluster encoding 59 mature
Figure 1 miR-372 was upregulated in 2 of 114 thyroid carcinomas. (A) Relative expression of miR-372 was quantified in 114 thyroid
carcinoma samples of different types (PTC: papillary thyroid carcinoma, FTC: follicular thyroid carcinoma, ATC: anaplastic thyroid carcinoma, MTC:
medullary thyroid carcinoma, OTC: oncocytic thyroid carcinoma). Expression is compared to three different normal thyroid tissues. The thyroid
tissue showing the highest expression of miR-372 was used as calibrator. A thyroid adenoma with 19q13.4 rearrangement (S1016) served as a
positive control of abundant miR-372 expression. The arrows indicate the samples that also appear in Figure 3 (from left to right: normal thyroid
tissue, S1016, KS 99, KS 97, KS 61, KS 41, KS 82, KS 106, KS 100, KS 13). RQ: relative quantity (logarithmic scale). The lower panel shows histological
sections of (B) case KS 13, a follicular variant of papillary thyroid carcinoma (PTC) and (C) case KS 100, an anaplastic thyroid carcinoma (ATC).
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members are abundantly expressed in embryonic stem
cells (ESC) and in the placenta where strong expression
is even detectable at term. The cluster is apparently con-
trolled by an adjacent CpG island [6]. Maternal methyla-
tion leads to an almost exclusive expression of the
paternal allel which, however, also becomes epigeneti-
cally silenced in the embryoblast while the “original”, i.e.
ESC-like, methylation pattern persists in the placenta.
Relatively little is known about the function of that clus-
ter and putative targets of its miRNAs. Although differ-
ent miRNAs of C19MC have been shown to promote
proliferation, invasion and other oncogenic functions
[16,26,27], some have also been linked to tumor suppres-
sive properties [28-30]. Overall there are thus conflicting
data as to the functions of C19MC miRNAs [for sum-
mary see [20]] that so far give no sufficient explanation
as to how these miRNAs contribute to the development
of thyroid adenomas.
The second cluster affected by the 19q13.4 transloca-
tion seen as recurrent clonal chromosomal abnormalitiesin thyroid adenomas is much smaller. miR-371-3 only
encodes five miRNAs and has orthologues in most
mammalian species. This cluster is also abundantly
expressed in embryonic stem cells and its re-expression
in malignant tumors has been associated with invasive-
ness in a couple of studies [16-19]. These latter findings
led us to suggest that activation of this cluster in thyroid
adenomas may predispose these lesions to malignant
transformation. If this hypothesis holds true one would
expect this cluster to be overexpressed in subgroups of
thyroid carcinomas from thyroid follicular epithelium.
Interestingly, of 114 malignant thyroid tumors no lesion
displayed an expression pattern akin to that seen in thy-
roid adenomas with 19q13.4 translocations, i.e. the sim-
ultaneous overexpression of genes of both clusters. In
contrast, two tumors were found to overexpress miR-372
and miR-371a-3p but did neither abundantly express miR-
520c-3p and miR-519a-3p nor displayed 19q13.4 rearran-
gements after FISH using appropriate DNA probes.
There is little doubt that chromosomal translocations
involving 19q13.4 are causally associated with the
Figure 2 Relative expression of miR-372 in case KS 13 and
surrounding normal tissue. Surrounding normal tissue (ST) was
obtained from another FFPE block of the same sample. Expression is
compared to normal thyroid tissue and a thyroid adenoma with
19q13.4 rearrangement (S1016) as positive control.
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Though highly recurrent, the mechanism by which
they contribute to tumorigenesis is unknown. By these
translocations involving varying translocation partners
two gene clusters of miRNAs whose members have
been associated with malignant growth are reactivated.
Nevertheless, from the results of the present study
as well as from data obtained on adenomas [5] no evi-
dence exists that in thyroid tumors overexpression of
both clusters resulting from 19q13.4 rearrangements
characterizes lesions with the capability to invadesurrounding tissue, i.e. to undergo malignant transform-
ation. Thus, their function in adenomagenesis still
remains to be elucidated.
Conclusion
Upregulation of the two miRNA clusters C19MC and
miR-371-3 does not seem to characterize a major pathway
of malignant transformation of the thyroid epithelium.
Methods
Tissues
FFPE tumor samples used for the analyses were retrieved
from the archive of one of the authors (K. J.).
RNA isolation
RNA was isolated using the High Pure RNA Paraffin Kit
(Roche Applied Science, Mannheim, Germany) as out-
lined below with modifications for the recovery of small
RNAs according to Tang et al. [31].
100 μl tissue lysis buffer, 16 μl 10% SDS and 40 μl pro-
teinase K were added to three 5 μm sections of FFPE
tissue and the mixture was incubated for 15 min at 65°C
and another 15 min at 80°C. After addition of 325 μl
binding buffer the mixture was added to 350 μl absolute
ethanol preliminarily put onto a High Pure filter tube.
After centrifugation for 20 s at 8,000 × g the flow-
through was discarded and the filter tube centrifuged
again with the same conditions to dry the filter tube
membrane. The membrane was then washed consecu-
tively with 500 μl wash buffer I, 500 μl wash buffer II
and 300 μl wash buffer II followed by centrifugation for
20 s at 8,000 × g, respectively, and a terminal centrifuga-
tion for 2 min at full speed to remove excess buffer.
A mix consisting of 4 μl DNase, 6 μl 10x DNase buffer,
and 50 μl aqua bidest was put onto the membrane and
incubated for 30 min at 37°C. The DNase treatment was
followed by another three wash steps with wash buffer I
and II and centrifugations as described above. The RNA
was then eluted by putting 50 μl elution buffer onto the
membrane, incubating for 1 min and centrifuging for
1 min at 8,000 × g. RNA concentration was measured on
a Biophotometer (Eppendorf, Hamburg, Germany).
Quantitative real-time PCR for detection of miR-372,
miR-371a-3p, miR-520c-3p, and miR-519a-3p
Reverse transcription of miR-372, miR-371a-3p, miR-
520c-3p, miR-519a-3p, and RNU6B (for normalization) was
conducted using the TaqMan MicroRNA Reverse Tran-
scription Kit (Life Technologies Corporation, Carlsbad,
USA) according to the manufacturer´s instructions.
Real-time PCR was conducted on an ABI 7300 Real-
time PCR system using TaqMan MicroRNA Assays (Life
Technologies cat. no. 4427975; assay names hsa-miR-371-
3p, hsa-miR-372, hsa-miR-520c-3p, hsa-miR-519, RNU6B)
Figure 3 Relative expression of miR-371a-3p, miR-520c-3p, and miR-519a-3p in thyroid carcinoma samples. (A) Relative expression of
miR-371a-3p was quantified in five thyroid carcinoma samples of different histological subgroups. (B) Relative expression of miR-520c-3p was
quantified in 114 thyroid carcinoma samples of different types (as no upregulation was observed in any of the samples only a selection of
samples is shown including the three cases with the highest expression of miR-520c-3p. (C) Relative expression of miR-519a-3p in five thyroid
carcinoma samples of different types. In A,B and C the expression is compared to normal thyroid tissue and a thyroid adenoma with 19q13.4
rearrangement (S1016) as positive control. RQ: relative quantity (logarithmic scale). PTC: papillary thyroid carcinoma, FTC: follicular thyroid
carcinoma, ATC: anaplastic thyroid carcinoma.
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nologies) according to the manufacturer´s instructions.
Fluorescence in situ hybridization
To detect or exclude rearrangements of 19q13.4,
cases with elevated expression were further analyzed
by FISH using a dual-color, break-apart probe of
the thyroid breakpoint cluster 19q13.4 (TBPC19)
(PanPath, Budel, Netherlands) on FFPE tissue sec-
tions as described previously [32]. For pretreatmentFigure 4 Fluorescence in situ hybridization for the detection of 19q13
(FISH) was carried out with a dual-color break-apart rearrangement probe (
cases KS 13 (A), KS 100 (B), and the positive control S1016 (C), respectively.
balanced translocation t(2;19)(p13;q13.4) is shown (D).of 4 μm tissue sections digestion with a pepsin
ready-to-use solution (DCS, Hamburg, Germany) was
performed at 37°C for 2 × 45 min (case KS 100) and
1 × 30 min (case KS 13), respectively.
Images were captured with a high performance CCD-
camera (Visitron Systems, Puchheim, Germany) and edi-
ted with FISH View (Applied Spectral Imaging, Migdal
HaEmek, Israel). 200 non-overlapping nuclei from at
least four different areas of the tumor were scored. As a
control 100 non-overlapping nuclei from non-neoplastic.4 rearrangements. Interphase fluorescence in situ hybridization
TBPC19; thyroid adenoma breakpoint cluster 19q13.4) for nuclei of
In addition, a partial karyotype of the latter case with an apparently
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were scored. Two fusion signals indicate a non-
rearranged thyroid breakpoint cluster 19q13.4, whereas
one fusion signal along with a single green and a single
red signal indicate a rearrangement of the thyroid break-
point cluster 19q13.4. As a positive control, FISH was
performed on cytological smears of S1016 as described
previously [33].
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